The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. (The other three are Adderall XR, Vyvanse and the Daytrana patch.) There are about 11 drugs on ...

Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch. Matthew Cabrey, a spokesperson for ...

Patient materials for Shire’s ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA’s Division of Drug Marketing, ...

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...

INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...

Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...

"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...

Days after announcing plans to sue Teva Pharmaceutical Industries over patent infringement of Intuniv, Shire has been informed that another company is hoping to launch its generic version of the ...